Myocardial InfarctionAIDE-CP1NCT07864038
AI-based Decision Support in Acute Chest Pain
A study testing AIDE-CP available in people with Myocardial Infarction and Chest Pain, run by Region Skane.
Trial summary
The AIDE-CP1 trial will test whether a decision support tool based on artificial intelligence (AI) can improve care for patients who come to an emergency department with chest pain. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Myocardial Infarction, Chest Pain
- What is being tested?
- AIDE-CP available
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,500 participants
- Where
- No sites listed yet
- Study dates
- 18 Jan 2027to Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Non-traumatic chest pain, presentation to the ED.
Who cannot join
- Patient declining participation.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Randomized Controlled Trial of an AI-based Decision Support in Emergency Department Chest Pain Patients (AIDE-CP1)
The AIDE-CP1 trial will test whether a decision support tool based on artificial intelligence (AI) can improve care for patients who come to an emergency department with chest pain. The AI tool uses the patient's age, sex, first blood tests and ECG to estimate the risk of a heart attack within 30 days and suggests what to do next. About 4,500 patients at five Swedish emergency departments will be included. The study will examine whether the AI tool can shorten time spent in the emergency department while maintaining patient safety. It will also study healthcare use, costs, and how AI affects doctors' decisions.
Read the detailed description
The AIDE-CP1 trial is a multicenter, randomized controlled trial evaluating whether an artificial intelligence-based clinical decision support system can improve the management of adults presenting to emergency departments (EDs) with chest pain. AIDE-CP integrates age, sex, initial laboratory results, and ECG data to estimate the 30-day probability of acute myocardial infarction (AMI) and provides risk-based management recommendations.
Approximately 4,500 unselected adult chest pain patients will be included across five Swedish EDs. Randomization occurs at the level of the study day, with AIDE-CP either available to clinicians or unavailable, in which case patients receive standard care. The primary outcome is ED length of stay among patients discharged from the ED. Secondary outcomes include 30-day AMI and major adverse cardiac events, admission and discharge rates, time to disposition, downstream healthcare utilization and costs, and effects on overall ED patient flow.
A nested substudy of 400 patients will assess how AIDE-CP influences physicians' estimates of AMI probability and clinical decision-making. The trial is designed to determine whether integrating AI-based risk prediction into routine emergency care can accelerate patient management while maintaining safety, and to provide prospective evidence on the real-world clinical impact of AI-supported decision-making.
- Conditions
- Myocardial Infarction, Chest Pain
- Being tested
- AIDE-CP available
- Keywords
- Emergency department, Artificial intelligence, Acute myocardial infarction, Chest pain
- Medical subject headings
- Myocardial Infarction, Chest Pain, Emergencies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AIDE-CP availableOther
On randomized days, AIDE-CP is available to the ED physicians
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Active comparator | AIDE-CP available Receives: Other: AIDE-CP available |
| Control | No intervention | Standard care |
What is being measured
The primary outcome is the main question the study is designed to answer.
EDLOS
Emergency department (ED) length of stay (LOS) in minutes in patients discharged home from the ED
Measured: Up to 24 hours
Secondary outcomes (7)
30-day AMI and MACE in discharged patients
30-day (including index visit) acute myocardial infarction (AMI) and major adverse cardiac events (MACE) incidence in discharged patients.
Measured: 30 days from ED arrival
30-day ED revisits with admissions
ED revisits within 30 days with admissions to inpatient care
Measured: Up to 30 days
Accuracy of AIDE-CP AMI prediction in all patients
Accuracy of AIDE-CP's 30-day AMI predictions (sensitivity, specificity, etc) in all patients; i.e. including patients where AIDE-CP is unavailable at the ED.
Measured: Up to 30 days
Time to disposition in in all patients
Time from ED arrival to decision regarding hospital admission or discharge home from the ED, in all patients
Measured: Up to 24 hours
Proportion of patients discharged from the ED
Number of patients discharged from the ED divided by all included patients
Measured: Up to 24 hours
Difference in physician estimates before and after AIDE-CP access.
Difference in physician estimates of 30-day AMI risk before versus after AIDE-CP access.
Measured: Up to 24 hours
Output of AIDE-CP versus physician risk group assignment
Difference in risk group assignment of AIDE-CP versus physician before and after AIDE-CP access
Measured: Up to 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2026
- Study start18 Jan 2027 (estimated)
- Primary completionJun 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 4,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Region Skane
- Sponsor type
- University, hospital or other
- Collaborators
- Lund University
- Responsible party
- Sponsor
- Investigators
- Ulf Ekelund, MD, PhD, Study chair, Region Skåne, Lund University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07864038
- Sponsor's protocol ID
- Dnr 2026-05031-01
- Acronym
- AIDE-CP1
- Status last verified
- Oct 2026
- First submitted
- 28 Sep 2026
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Confidential patient information according to the GDPR legislation within the European Union.
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Trial of an AI-based Decision Support in Emergency Department Chest Pain Patients (AIDE-CP1)
- ClinicalTrials.gov ID
- NCT07864038
- Acronym / sponsor ID
- AIDE-CP1 / Dnr 2026-05031-01
- Conditions
- Myocardial Infarction, Chest Pain
- Keywords
- Emergency department, Artificial intelligence, Acute myocardial infarction, Chest pain
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 4,500 participants (estimated)
- Lead sponsor
- Region SkaneUniversity, hospital or other
- Collaborators
- Lund University
- Study start
- 18 Jan 2027 (estimated)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 7 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The AIDE-CP1 trial will test whether a decision support tool based on artificial intelligence (AI) can improve care for patients who come to an emergency department with chest pain. The AI tool uses the patient's age, sex, first blood tests and ECG to estimate the risk of a heart attack within 30 days and suggests what to do next. About 4,500 patients at five Swedish emergency departments will be included. The study will examine whether the AI tool can shorten time spent in the emergency department while maintaining patient safety. It will also study healthcare use, costs, and how AI affects doctors' decisions.
Detailed description
The AIDE-CP1 trial is a multicenter, randomized controlled trial evaluating whether an artificial intelligence-based clinical decision support system can improve the management of adults presenting to emergency departments (EDs) with chest pain. AIDE-CP integrates age, sex, initial laboratory results, and ECG data to estimate the 30-day probability of acute myocardial infarction (AMI) and provides risk-based management recommendations.
Approximately 4,500 unselected adult chest pain patients will be included across five Swedish EDs. Randomization occurs at the level of the study day, with AIDE-CP either available to clinicians or unavailable, in which case patients receive standard care. The primary outcome is ED length of stay among patients discharged from the ED. Secondary outcomes include 30-day AMI and major adverse cardiac events, admission and discharge rates, time to disposition, downstream healthcare utilization and costs, and effects on overall ED patient flow.
A nested substudy of 400 patients will assess how AIDE-CP influences physicians' estimates of AMI probability and clinical decision-making. The trial is designed to determine whether integrating AI-based risk prediction into routine emergency care can accelerate patient management while maintaining safety, and to provide prospective evidence on the real-world clinical impact of AI-supported decision-making.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Active comparator | Other: AIDE-CP availableAIDE-CP available |
| Control | No intervention | –Standard care |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Non-traumatic chest pain, presentation to the ED.
Key exclusion criteria (1 listed)
- Patient declining participation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AIDE-CP availableOn randomized days, AIDE-CP is available to the ED physicians | Other | Intervention |
Primary outcome
EDLOS
Time frame: Up to 24 hours
Emergency department (ED) length of stay (LOS) in minutes in patients discharged home from the ED
7 secondary outcomes
30-day AMI and MACE in discharged patients
Time frame: 30 days from ED arrival
30-day ED revisits with admissions
Time frame: Up to 30 days
Accuracy of AIDE-CP AMI prediction in all patients
Time frame: Up to 30 days
Time to disposition in in all patients
Time frame: Up to 24 hours
Proportion of patients discharged from the ED
Time frame: Up to 24 hours
Difference in physician estimates before and after AIDE-CP access.
Time frame: Up to 24 hours
Output of AIDE-CP versus physician risk group assignment
Time frame: Up to 24 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Individual participant dataSharing planned: No. Confidential patient information according to the GDPR legislation within the European Union.
Related trials for Myocardial Infarction
Recruiting
ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
Myocardial Infarction (MI), Sudden Cardiac Death Due to Cardiac Arrhythmia
RecruitingObservational study
Breisgau PHENO-HEART MI
Myocardial Infarction, STEMI
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
Recruiting
CRP Apheresis in Infarct-Related Cardiogenic Shock
Cardiogenic Shock, Acute Myocardial Infarction (AMI)
Recruiting
Reducing Slow/No-Reflow With Prophylactic High-Dose Intracoronary Adenosine Protocol in ST-Elevation Myocardial Infarction The REFLOW AMI Trial
ST-Elevation Myocardial Infarction (STEMI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ulf Ekelund, MD, PhD study chair
Region Skåne, Lund University
Questions about this trial
What is this clinical trial studying?
A study testing AIDE-CP available in people with Myocardial Infarction and Chest Pain, run by Region Skane.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ulf Ekelund, MD, PhD (+4646176744, ulf.ekelund@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
EDLOS (time frame: Up to 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.